Novo Nordisk's brand name for semaglutide for type 2 diabetes, sold as a weekly injection and, since May 2026 in the US, as daily Ozempic tablets.
Updated Sep 26, 2026
Ozempic is Novo Nordisk's brand name for semaglutide prescribed for type 2 diabetes. It began as an injection dosed weekly. Since May 4, 2026 it has also been sold in the US as once-daily Ozempic tablets (1.5 mg, 4 mg and 9 mg), which replace the older oral brand Rybelsus (Novo Nordisk ↗ (external link)).
As of September 2026, the injection is FDA-approved for three uses in adults with type 2 diabetes: improving blood sugar control, lowering the risk of major cardiovascular events in people with established heart disease, and lowering the risk of worsening kidney disease, kidney failure and cardiovascular death in people with chronic kidney disease (Ozempic prescribing information ↗ (external link)). The tablets are approved for two uses in adults with type 2 diabetes: improving blood sugar control, and lowering the risk of major cardiovascular events in people at high risk for them (Ozempic tablets and Rybelsus prescribing information ↗ (external link)).
Ozempic is not approved for weight management, though it has been prescribed off-label for weight loss. Wegovy has the same active ingredient and is the semaglutide brand approved for weight management.
Was this helpful?
Revision history
Last updated · 3 revisions recorded.
Show what changed
v3
Body revised
v2
Summary rewritten; Body revised; Metadata updated
v1
Existing article recorded at the start of version history
Improve this page▾
Community notes
Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.
Loading notes…
New submissions are currently paused. Existing approved notes remain available.
Related terms
Hazard ratio — A statistic from clinical trials that compares how often an event happens over time in one group versus another; below 1 means a lower rate in the treated group.
Sharps container — A puncture-resistant container for safely collecting used needles, pen needles, and syringes until they can be disposed of according to local rules.
Oral semaglutide — Semaglutide taken as a once-daily pill instead of a weekly injection: Rybelsus and its reformulation, Ozempic tablets, for type 2 diabetes, and the Wegovy pill for weight management.
Related guides
Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis — GLP-1 medications slow the stomach, but the trials show the effect is smaller and fades more than most people assume, especially with the long-acting weekly drugs. This guide covers how much slower, whether it lasts, how gastric emptying is measured, how it differs from gastroparesis, and why the "food ferments in your stomach" claim has no evidence behind it.
Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration — Missed a few weeks of Wegovy, Zepbound, Ozempic, Trulicity, Saxenda, or a GLP-1 pill? Only four labels spell out when to restart at a lower dose: Wegovy injection after 2 missed weekly doses, Saxenda and Victoza after more than 3 days, and Foundayo after 7 missed daily doses. The rest are silent on long gaps. This by-drug reference separates what each label says from what's left to your prescriber, and explains why going straight back to your old dose is risky.
Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo — There are now three GLP-1 pills in the US, and they aren't interchangeable: oral semaglutide for diabetes (Rybelsus, now sold as Ozempic tablets), oral semaglutide for weight (the Wegovy pill), and orforglipron (Foundayo). Here's how they compare on approval, how you take them, what the trials found, side effects, cost, and what you give up versus a weekly injection.